Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated hepatitis A vaccine (TZ84 strain)
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Inactivated HAV Vaccine, TZ84 Strain is a biological vaccine developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS) for the prevention of hepatitis A infection. It utilizes the TZ84 strain of the hepatitis A virus (HAV), which has been adapted to replicate in vitro and is subsequently inactivated. The vaccine is administered intramuscularly, typically in a two-dose schedule with a booster at six months. Clinical studies have demonstrated that the TZ84-strain vaccine provides superior immunogenicity, with protection potentially lasting up to 30 years, and exhibits fewer adverse reactions compared to other inactivated hepatitis A vaccines. It has also shown efficacy in controlling community-wide outbreaks.
- Other names
- inactivated hepatitis A vaccine TZ84Inactivated HAV Vaccine, TZ84 Strain
02
Targets
BCR (Immunoglobulin G B Cell Receptor)PRR (Pattern recognition receptors)Hepatitis A virus capsid protein
Beyond the preview
Go deeper on inactivated hepatitis A vaccine (TZ84 strain).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated hepatitis A vaccine (TZ84 strain).